Share this article
Share this article
LUND, Sweden, March 11, 2021 /PRNewswire/ BioInvent International AB ( BioInvent ) (Nasdaq Stockholm: BINV), today announces the publication of proof-of-concept data on a novel, fully human FcγRIIB-blocking antibody, BI-1607, at the American Association for Cancer Research (AACR) Annual Meeting 2021, being held virtually April 10-15 and May 17-21. The data on BI-1607 are very exciting and provide proof-of-concept of its ability to enhance anti-cancer immunity, illustrated by its ability to boost activity and overcome resistance to CTLA-4-based therapy, said
Martin Welschof, CEO of BioInvent. We are looking forward to advancing BI-1607 into clinical development and expect to submit a clinical trial application during H2 2021. It will be BioInvent s fourth drug candidate in clinical development, further demonstrating the strength and productivity of our technology platform.
Ascentage Pharma to Present the Latest Results from Six Preclinical Studies at AACR Annual Meeting 2021
News provided by
Share this article
Share this article
SUZHOU, China and ROCKVILLE, Md., March 10, 2021 /PRNewswire/ Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the latest preclinical research results of the company s five novel drug candidates have been selected for presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021, and have already been published in the meeting s official website. This year s AACR annual meeting will be held in a virtual format on April 27-28 and June 22-24.
PharmAbcine to Present at AACR Annual Meeting 2021
News provided by
Share this article
Share this article
DAEJEON, South Korea, March 11, 2021 /PRNewswire/ PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today an e-poster presentation featuring nonclinical data of PMC-309 at American Association for Cancer Research (AACR) Annual Meeting. The meeting will take place virtually over April 10-15 and May 17-21 2021.
Presentation Details
Title: PMC309, a highly selective anti-VISTA antibody enhances T cell activation through blocking the interaction of T cells and myeloid derived suppressor cells (MDSC)
Session category/title: Immunology/Immune Checkpoints
Imguene Ltd to present on CF33 and HER-Vaxx immunotherapy programs at American Association for Cancer Research annual meeting proactiveinvestors.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com.au Daily Mail and Mail on Sunday newspapers.
Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021
SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced publication of abstracts for three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting. The AACR Annual Meeting Week 1 will be held virtually from April 10-15, 2021. Posters will be available on Harpoon’s website following the presentations.
Full abstracts of the following presentations are available online at www.aacr.org:
Title: FLT3-targeting TriTACs are T cell engagers for treatment of acute myeloid leukemia